Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 67
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Imf Cuts U.s. 2014 Growth Forecast To 1.7%
The International Monetary Fund revised its growth outlook for the U.S. economy for the second time in two months after a first-quarter contraction turned out to be worse than the fund originally forecast.
More Top Equities Stories Of The Day
Crash Investigators Face Difficult Task in Ukraine
European Stocks Slip; Shire Leads FTSE Gains
Have Big-Screen Smartphones Crashed the Tablet Party?
ADR Shares End Mixed; GlaxoSmithKline Shares Trade Actively
Taiwan Export Orders Point to Stronger Global Demand
Judge Delays Decision on Argentine Bonds
U.S. Hot Stocks: Hot Stocks to Watch
Alstom Orders Double but Sales Fall
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 180668 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist